Actively Recruiting

All Genders
Healthy Volunteers
NCT06126692

3TR Asthma Biologics Cohort (ABC) Study

Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2023-11-13

600

Participants Needed

2

Research Sites

603 weeks

Total Duration

On this page

Sponsors

A

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Lead Sponsor

B

Bispebjerg Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The 3TR-ABC study is a multicentre observational prospective cohort study platform that follows patients with severe asthma from the start of biological therapy and three years onwards. In the 3TR-ABC platform, individual studies are conducted on specific biologics, using aligned study designs. The aim of the study is to assess response to treatment and examine clinical characteristics, biomarkers, and immunological mechanisms related to response, including remission and non-response, that might be new targets or explanations for insufficient treatment. Patients will be extensively characterized at baseline and then followed throughout the years with formal clinical and biological assessment at 4, 16, 52 weeks, and 2, 3 years. Based on the response to treatment, patients will be stratified into remission, clinical responders, and non-responders, and pre-treatment biomarker profiles obtained at the baseline visit will be compared, as well as the immunological response to treatment. Healthy individuals and patients with mild/moderate controlled asthma are included as reference groups and will undergo the same baseline visit as patients with severe asthma. Several bio-samples, to perform multi-omic analysis, will be taken to examine biological pathways associated with response and non-response to biologics.

CONDITIONS

Official Title

3TR Asthma Biologics Cohort (ABC) Study

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with severe asthma requiring high dose inhaled corticosteroids plus LABA, LTRA, or LAMA, or fixed oral prednisolone treatment at least 50% of the time
  • Patients with a minimum of 2 asthma exacerbations in the last year or oral prednisolone use at least 50% of the time
  • Asthma Control Questionnaire (ACQ) score greater than 1.5
  • Patients who meet national criteria for specific biologic treatment
  • Patients with mild/moderate asthma requiring low/medium dose inhaled corticosteroids plus LABA with or without LTRA
  • ACQ score less than 1.5 for mild/moderate asthma
  • No exacerbations or need for oral prednisolone treatment in the last year for mild/moderate asthma
  • Markers of type 2 inflammation (blood eosinophils ≥0.15 actual or ≥0.30 in last year, sputum eosinophils ≥3%, FeNO ≥25, or allergen positivity) for mild/moderate asthma
  • Healthy volunteers with no respiratory diseases, no history of asthma or respiratory symptoms, normal lung function, no history of allergies, and no respiratory infections in the past 4 weeks
Not Eligible

You will not qualify if you...

  • Known hypersensitivity to the active substance or any excipients
  • Participation in an interventional clinical trial or receipt of investigational medicinal product within 3 months or 5 half-lives prior to visit 1
  • Other significant or uncontrolled medical diseases likely to affect therapy or study participation
  • Unable to understand written information due to language barriers (mild/moderate asthma and healthy volunteers)
  • Unable to provide informed consent (mild/moderate asthma and healthy volunteers)
  • Signs of uncontrolled asthma including ACQ score higher than 1.5, oral corticosteroid use, or history of exacerbations within the past year (mild/moderate asthma)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Bispebjerg Hospital

Copenhagen, Denmark, 2400

Actively Recruiting

2

Amsterdam University Medical Center

Amsterdam, North Holland, Netherlands, 1105AZ

Actively Recruiting

Loading map...

Research Team

S

Susanne Vijverberg, Dr.

CONTACT

P

Peter Bonta, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here